

PERSONAL INFORMATION

Family name, First name: La Mura, Vincenzo

Date of birth: May 8th 1977

Nationality: Italian

Researcher unique identifier(s): ORCID 0000-0003-4685-7184, Research ID M-3949-2016,

Scopus author ID: 23008586600

Current position: Assistant Professor of Internal Medicine - Department of Biomedical Sciences for Health, University of Milan, Italy - academic tenure track position for the Italian system

EDUCATION and TITLES

- **2017 National licence from the Italian Minister of University and Research to being Associate professor in Internal Medicine** (originally: “Abilitazione scientifica nazionale a Prof. II fascia, SSD 6/B1, MED/09, Medicina Interna”)
- **2017 National licence from the Italian Minister of University and Research to being Associate Professor in Gastroenterology and Infectious Diseases** – (originally: “Abilitazione scientifica nazionale a Prof. II fascia, SSD 6/D4, Malattie Cutanee, Malattie Infettive e Malattie Dell'apparato Digerente”)
- **2011 Biostatistics for Health Sciences** (n=30 ECTS)
Universitat Autònoma de Barcelona, Spain
Score: 8.2/10.0
Acquired Skills: analysis and statistical design of experimental and observational studies. Systematic revision and meta-analysis.
- **2010: Licence for the use of animal models for experimental research** from Generalitat de Catalunya-Departament de Medi Ambient i Habitatge, Direcció General del Medi Natural (Decret 214/1997)
- **2010 PhD in Medicine**
Hepatic Hemodynamic Laboratory-Hospital Clinic, IDIBAPS, Universitat de Barcelona, SPAIN
Name of PhD Supervisor: Prof. Jaime Genover Bosch
Score: sobresaliente cum laude (maximum score with merit)
Acquired Skills: liver and systemic hemodynamic studies in humans and in animal models of cirrhosis, endotoxemia, liver steatosis. Molecular analysis through western blot, ELISA. Morphological analysis by light microscope and immune-histochemistry.
- **2007 Specialty in Internal Medicine**
Seconda Università degli studi di Napoli, ITALY
Score: 50/50 cum laude (maximum with merit)
Acquired Skills: management of in-patients and out-patients with acute and chronic liver disease, management of patients with cardio-vascular risk, metabolic diseases, infectious diseases, general management of critical patients with hepatic and non-hepatic organ failure
- **2002 Medical Doctor (MD)**
Seconda Università degli studi di Napoli, ITALY
Score: 110/110 e lode (maximum with merit)
Acquired Skills: general overview of medicine and surgery

PREVIOUS ACCADEMIC POSITIONS

- **2014-2017 – Assistant Professor of Internal Medicine** - temporary position - Department of Biomedical Sciences for Health
- **2012 – 2014 Post-doc researcher and Medical Doctor**
IRCCS Ospedale Maggiore, Ca' Granda, Milano, Università degli studi di Milano, ITALY
- **2010 – 2012 Post-doc researcher**
Hepatic Hemodynamic Laboratory-Hospital Clinic, IDIBAPS, Universitat de Barcelona, SPAIN
- **2007 – 2010 PhD student**
Hepatic Hemodynamic Laboratory-Hospital Clinic, IDIBAPS, Universitat de Barcelona, SPAIN
- **2002 – 2007 Residency student in Internal Medicine**
Medicina Interna e malattie epato-blilio-metaboliche avanzate, Seconda Università degli studi di Napoli, ITALY

PREVIOUS HOSPITAL POSITION

- **2014-2017 Internal Medicine, IRCCS San Donato**, University of Milan, San Donato Milanese (MI) Italy
- **2012-2014 Gastroenterology, IRCCS Ca' Granda, Ospedale Maggiore Policlinico**, University of Milan, San Donato Milanese (MI)_Italy
- **2007-2012 Hepatic Hemodynamic Laboratory-Hospital Clinic**, IDIBAPS, University of Barcelona, SPAIN
- **2002-2007 Internal Medicine Medicina Interna e malattie epato-blilio-metaboliche avanzate**, Seconda Università degli studi di Napoli (oggi Università degli studi della Campania, Luigi Vanvitelli).
Ruolo: specializzando con borsa

Rotazione formativa durante la specializzazione:

- Ospedale San Paolo, U.O. Medicina d'Urgenza, Napoli (6 months)
- Ospedale evangelico-Villa Betania, U.O. Medicina Interna e pronto soccorso (4 months)
- Ospedale civile di Caserta, UTIC, Caserta (2 months)
- Hospital Clinic i Provincial- Universitat de Barcelona, Barcellona, Spagna (12 months: Erasmus-Socrates program)

FELLOWSHIPS

- **2007-2012** Scholarship of 60 months for the **pre-doc (2007-2010), post-doc (2010-2012) training at the University of Barcelona, Spain**, under the supervision of Prof. Jaime Bosch, Liver Unit, Hepatic hemodynamic Laboratory, Hospital Clinic I Provincial
- **2005 – 2006** Scholarship of 12 months, **ERASMUS-Socrates European Exchange Programme** at the **University of Barcelona, Spain**, under the supervision of Prof. Jaime Bosch, Liver Unit, Hepatic hemodynamic Laboratory, Hospital Clinic I Provincial

LIST OF ARTICLES PUBLISHED ON IMPACT FACTOR JOURNALS (reverse chronological order of publication):

1. Baiges A, Turon F, Simón-Talero M, Tasayco S, Bueno J, Zekrini K, Plessier A, Franchi-Abella S, Guerin F, Mukund A, Eapen CE, Goel A, Shyamkumar NK, Coenen S, De Gottardi A, Majumdar A, Onali S, Shukla A, Carrilho FJ, Nacif L, Primignani M, Tosetti G, **La Mura V**, Nevens F, Witters P, Tripathi D, Tellez L, Martínez J, Álvarez-Navascués C, Fraile López ML, Procopet B, Piscaglia F, de Koning B, Llop E, Romero-Cristobal M, Tjwa E, Monescillo-Francia A, Senzolo M, Perez-LaFuente M, Segarra A, Sarin SK, Hernández-Gea V, Patch D, Laleman W, Hartog H, Valla D, Genescà J, García-Pagán JC; REHEVASC, VALDIG an EASL consortium, Abernethy group. Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. *Hepatology*. 2019 Jun 18. doi: 10.1002/hep.30817. [Epub ahead of print]
2. Turco L, Villanueva C, **La Mura V**, García-Pagán JC, Reiberger T, Genescà J, Groszmann RJ, Sharma BC, Merkel C, Bureau C, Alvarado E, Abraldes JG, Albillos A, Bañares R, Peck-Radosavljevic M, Augustin S, Sarin S, Bosch J, García-Tsao G. Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without

- Ascites: A Meta-Analysis. **Clin Gastroenterol Hepatol**. 2019 Jun 5. pii: S1542-3565(19)30601-9. doi: 10.1016/j.cgh.2019.05.050. [Epub ahead of print]
3. Tosetti G, Primignani M, **La Mura V**, D'Ambrosio R, Degasperi E, Mezzina N, Viganò M, Rumi M, Fracanzani AL, Lombardi R, Fargion S, Fraquelli M, Aghemo A, Lampertico P. Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease. **Dig Liver Dis**. 2019[Epub ahead of print]
 4. Reverter E, Lozano JJ, Alonso C, Berzigotti A, Seijo S, Turon F, Baiges A, Martínez-Chantar ML, Mato JM, Martínez-Arranz I, **La Mura V**, Hernández-Gea V, Bosch J, García-Pagán JC. Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. **Liver Int**. 2019 Jan 13. doi: 10.1111/liv.14042. [Epub ahead of print]
 5. Di Pascoli M, **La Mura V**. Renin-angiotensin-aldosterone system in cirrhosis: There's room to try! **Dig Liver Dis**. 2018 Aug 23. pii: S1590-8658(18)30875-2. doi: 10.1016/j.dld.2018.07.038.
 6. **La Mura V**, Primignani M. Reply. **Clin Gastroenterol Hepatol**. 2018 Sep 13. pii: S1542-3565(18)30972-8. doi: 10.1016/j.cgh.2018.09.011. [Epub ahead of print]
 7. Bitto N, Liguori E, **La Mura V**. Coagulation, Microenvironment and Liver Fibrosis. **Cells**. 2018 24;7(8).
 8. Hernández-Gea V, Procopet B, Giráldez Á, Amitrano L, Villanueva C, Thabut D, Ibañez-Samaniego L, Silva-Junior G, Martinez J, Genescà J, Bureau C, Trebicka J, Llop E, Laleman W, Palazon JM, Castellote J, Rodrigues S, Gluud LL, Noronha Ferreira C, Barcelo R, Cañete N, Rodríguez M, Ferlitsch A, Mundi JL, Gronbaek H, Hernández-Guerra M, Sassatelli R, Dell'Era A, Senzolo M, Abraldes JG, Romero-Gómez M, Zipprich A, Casas M, Masnou H, Primignani M, Krag A, Nevens F, Calleja JL, Jansen C, Robic MA, Conejo I, Catalina MV, Albillos A, Rudler M, Alvarado E, Guardascione MA, Tantau M, Bosch J, Torres F, Garcia-Pagán JC; In Preemptive-TIPS improves outcome in high-risk variceal bleeding: An observational study. International Variceal Bleeding Observational Study Group and Baveno Cooperation. **Hepatology** 2018 Jul 16. doi: 10.1002/hep.30182. [Epub ahead of print]
 9. Sangiovanni A, Triolo M, Iavarone M, Forzenigo LV, Nicolini A, Rossi G, **La Mura V**, Colombo M, Lampertico P. Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations. **Liver Int**. 2018;38:1624-1634.
 10. Simón-Talero M, Roccarina D, Martínez J, Lampichler K, Baiges A, Low G, Llop E, Praktiknjo M, Maurer MH, Zipprich A, Triolo M, Vangrinsven G, Garcia-Martinez R, Dam A, Majumdar A, Picón C, Toth D, Darnell A, Abraldes JG, Lopez M, Kukuk G, Krag A, Bañares R, Laleman W, **La Mura V**, Ripoll C, Berzigotti A, Trebicka J, Calleja JL, Tandon P, Hernandez-Gea V, Reiberger T, Albillos A, Tsochatzis EA, Augustin S, Genescà J; Baveno VI-SPSS group from the Baveno Cooperation. Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. **Gastroenterology**. 2018;154(6):1694-1705
 11. **La Mura V.**, Braham S., Tosetti G., Branchi F, Bitto N, Moia M, Fracanzani AL, Colombo M, Tripodi A, Primignani M. Harmful and Beneficial Effects of Anti-coagulants in Patients With Cirrhosis and Portal Vein Thrombosis. **Clin Gastroenterol Hepatol**. 2018;16:1146-1152
 12. Pasarín M, Abraldes JG, Liguori E, Kok B, **La Mura V**. Intrahepatic vascular changes in non-alcoholic fatty liver disease: Potential role of insulin-resistance and endothelial dysfunction. **World Journal of Gastroenterology** 2017;23:6777-6787.
 13. **La Mura V**, Salerno F. Reply to the diagnostic conundrum of bacterial infections in cirrhotic patients. **Liver Int**. 2017;37:1412.
 14. De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B, Magenta L, Semela D, Buscarini E, Langlet P, Görtzen J, Puente A, Müllhaupt B, Navascués C, Nery F, Deltenre P, Turon F, Engelmann C, Arya R, Caca K, Peck-Radosavljevic M, Leebeek FWG, Valla D, Garcia-Pagan JC; **VALDIG Investigators**. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. **Liver Int**. 2017;37:694-699.
 15. Iavarone M, Primignani M, Vavassori S, Sangiovanni A, **La Mura V**, Romeo R, Colombo M. Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. **United European Gastroenterol J**. 2016;4:363-70.
 16. Salerno F, Borzio M, Pedicino C, Simonetti R, Rossini A, Boccia S, Cacciola I, Burroughs AK, Manini MA, **La Mura V**, Angeli P, Bernardi M, Dalla Gasperina D, Dionigi E, Dibenedetto C, Arghittu M; AISF Investigators. The

- impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. **Liver Int.** 2017;37:71-79.
17. Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). **Dig Liver Dis.** 2016;48:455-67.
 18. **La Mura V**, Tripodi A, Tosetti G, Cavallaro F, Chantarangkul V, Colombo M, Primignani M. Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis. **Liver Int.** 2016;36:1322-30.
 19. Primignani M, Tosetti G, **La Mura V**. Therapeutic and clinical aspects of portal vein thrombosis in patients with cirrhosis. **World J Hepatol.** 2015;7:2906-12
 20. **La Mura V**, Salerno F. Therapy of the refractory ascites: Total paracentesis vs. TIPS. **Gastroenterol Hepatol.** 2016;39:477-80
 21. de Souza AR, **La Mura V**, Berzigotti A, García-Pagán JC, Abraldes JG, Bosch J. Prognosis of acute variceal bleeding: is being on beta-blockers an aggravating factor? A short-term survival analysis. **Hepatology.** 2015;62:1840-6.
 22. Salerno F, **La Mura V**. Treatment of Spontaneous Bacterial Peritonitis. **Dig Dis.** 2015;33(4):582-5.
 23. Manini MA, Sangiovanni A, Martinetti L, Viganò D, **La Mura V**, Aghemo A, Iavarone M, Crespi S, Nicolini A, Colombo M. TACE with drug-eluting beads is effective for the maintenance of the milan-in status in patients with a small hepatocellular carcinoma. **Liver Transpl.** 2015 Oct;21(10):1259-69.
 24. de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. **J Hepatol.** 2015;63:743-52.
 25. **La Mura V**, Nicolini A, Tosetti G, Primignani M. Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. **World J Hepatol.** 2015;7:688-95
 26. **La Mura V**, Tosetti G, Primignani M, Salerno F. Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window. **World J Gastroenterol.** 2015;21:2265-8.
 27. Bitto N, Salerno F, Tripodi A, **La Mura V**. Coagulation and fibrosis: A potential non-negligible target of statins in chronic hepatitis. **J Hepatol.** 2015;63:277-8.
 28. **La Mura V**, Colombo M. Prophylaxis of rebleeding in hepatocellular carcinoma: pushing the envelope or a real clinical benefit? **Gastroenterology.** 2014;147:1177-9.
 29. **La Mura V**, Pasarín M, Rodríguez-Vilarrupla A, García-Pagán JC, Bosch J, Abraldes JG. Liver Sinusoidal Endothelial Dysfunction After LPS Administration: A Role for Inducible-Nitric Oxide Synthase. **J Hepatol.** 2014;61:1321-7.
 30. **La Mura V**, Colombo M. Bacterial translocation and nonselective β -blockers in portal hypertension: where we are, what we still need. **Gastroenterology.** 2014;147:247-9.
 31. Masarone M, De Renzo A, **La Mura V**, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. **BMC Gastroenterol.** 2014;14:31.
 32. **La Mura V**, Pasarín M, Meireles CZ, Miquel R, Rodríguez-Vilarrupla A, Hide D, Gracia-Sancho J, García-Pagán JC, Bosch J, Abraldes JG. Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. **Hepatology.** 2013;57:1172-81.
 33. Pasarín M, **La Mura V**, Gracia-Sancho J, García-Calderó H, Rodríguez-Vilarrupla A, García-Pagán JC, Bosch J, Abraldes JG. Sinusoidal Endothelial Dysfunction Precedes Inflammation and Fibrosis in a Model of NAFLD. **PLoS One.** 2012;7:e32785.
 34. **La Mura V**, Persico M. HCV infection, HOMA index and sustained virological response: The step we need to take before moving forward. **J Hepatol.** 2012;57:472.
 35. de Souza AR, **La Mura V**, Reverter E, Seijo S, Berzigotti A, Askenazhi E, García-Pagán JC, Abraldes JG, Bosch J. Patients Whose First Episode of Bleeding Occurs While Taking a β -Blocker Have High Long-term Risks of Rebleeding and Death. **Clin Gastroenterol Hepatol.** 2012;10:670-6.
 36. **La Mura V**, García Pagán JC. Antibiotic prophylaxis during bleeding for portal hypertension. **Aliment Pharmacol Ther.** 2011;34:1032-3.

37. Soverini V, Persico M, Bugianesi E, Forlani G, Salamone F, Massarone M, **La Mura V**, Mazzotti A, Bruno A, Marchesini G. HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. **Acta Diabetol.** 2011;48:337-43.
38. **La Mura V**, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, Abraldes JG, Bosch J, García-Pagán JC. Von Willebrand Factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. **Gut.** 2011;60:1133-8.
39. Pasarín M, Abraldes JG, Rodríguez-Vilarrupla A, **La Mura V**, García-Pagán JC, Bosch J. Insulin resistance and liver microcirculation in a rat model of early NAFLD. **J of Hepatol** 2011;55:1095-102.
40. **La Mura V**, Abraldes JG, Berzigotti A, Erice E, Flores-Arroyo A, García-Pagán JC, Bosch J. Right atrial pressure is not adequate to calculate portal-pressure gradient. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study. **Hepatol** 2010;51:2108-2116.
41. De Gottardi A, Hilleret MN, Gelez P, **La Mura V**, Guillaud O, Majno P, Hadengue A, Morel P, Zarski JP, Fontana M, Moradpour D, Mentha G, Boillot O, Leroy V, Giostra E, Dumortier J. Injection drug use before and after liver transplantation: a retrospective multicenter analysis on incidence and outcome. **Clin Transplant.** 2010;24:564-71.
42. Persico M, Russo R, Persico E, Svelto M, Spano D, Andolfo I, **La Mura V**, Capasso M, Tiribelli C, Torella R, Iolascon A. SOCS3 and IRS-1 gene expression differs between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells. **Clin Chem Lab Med.** 2009;47:1217-25.
43. **La Mura V**, Abraldes JG, , Raffa S, Retto O, Berzigotti A., García-Pagán JC, Bosch J. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. **J of Hepatol.**, 2009;51:279-87.
44. Persico M, Masarone M, **La Mura V**, Persico E, Moschella F, Svelto M, Bruno S, Torella R. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: Differences and similarities. **World J Gastroenterol** 2009;15:462-466.
45. **La Mura V**, De Renzo A, Perna F, D'Agostino D, Masarone M, Romano M, Bruno S, Torella R, Persico M. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma. **J Hepatol.** 2008; 4:557-63.
46. Masarone M, **La Mura V**, Bruno S, Gaeta GB, Vecchione R, Carrino F, Moschella F, Torella R, Persico M. Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease. **J Viral Hepat.** 2007;14:714-20.
47. Persico E, De Renzo A, **La Mura V**, Bruno S, Masarone M, Torella R, Persico M. Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-HBc positive patients. **Gut** 2007;56:1470-1.
48. Persico M, Capasso M, Persico E, Svelto M, Russo R, Spano D, Crocè L, **La Mura V**, Moschella F, Masutti F, Torella R, Tiribelli C, Iolascon A. Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. **Hepatology.** 2007;46:1009-15.
49. Palmentieri B, de Sio I, **La Mura V**, Masarone M, Vecchione R, Bruno S, Torella R, Persico M. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. **Dig Liver Dis.** 2006;38:485-9.
50. Persico M, Perrotta S, Persico E, Terracciano L, Folgari A, Ruggeri L, Nicosia A, Vecchione R, **Mura VL**, Masarone M, Torella R. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. **J Viral Hepat.** 2006;13:290-6.

CHAPTERS OF INTERNATIONAL BOOKS:

1. Title: "Role of comorbidities in the General Management of Compensated Cirrhosis, Including Malnutrition". Marika Rudler and Vincenzo La Mura. Portal Hypertension VI- Proceedings of Sixth Baveno International Consensus Workshop. Edited by Springer ISBN: 978-3-319-23017-7; year: 2016
2. Title: "Portal hypertension from molecular biology to clinical practice". Vincenzo La Mura and Jaime Bosch. Therapy in Liver Diseases, edited by ELSEVIER DOYMA ISBN: 978-84-7592-732-9; year: 2011

3. Title: "Statins in Portal Hypertension". Juan G Abraldes, Vincenzo La Mura and Jaime Bosch. Portal Hypertension V-Proceedings of fifth Baveno International Consensus Workshop, Fifth edition. Edited by Roberto de Franchis-Wiley-Blackwell ISBN: 978-1-4443-3449-4; year: 2011

COMMISSIONS OF TRUST

- **2012-at today– referee** for international Journals of the Gastroenterology and Hepatology area
- **2014- at today – Editorial Board**, World Journal of Gastroenterology
- **2014-2017 – Scientific Advisory Board** for the selection of abstracts submitted to the annual meeting of the European Association for the Study of Liver disease (EASL)
- **2014- at today – Scientific Advisory Board** for the selection of abstracts submitted to the annual meeting of the Italian Association for the Study of the Liver (AISF)
- **2015- at today – Assistant Editor** of Digestive and Liver Disease (official Journal of Italian Association for the Study of Liver Disease and the Italian Society of Gastroenterology)

ALL ON-GOING GRANTS AND FUNDING OF THE PI

- Project Title: LPS-induced intra-hepatic endothelial dysfunction: micro-thrombotic effects. Potential pharmacologic role of simvastatin.
Funding source Amount (Euros): IRCCS Ca' Granda research support for young investigators (fondo 5XMille per la ricerca, Italian Minister of health)-**30.000 euro**
Foreseen end of the Project: December 2017.
- Project Title: Vascular inflammation during sepsis causes prognosis worsening in patients with cirrhosis and portal hypertension: effects of simvastatin
Funding source Amount (Euros): Gilead Sciences Research Scholars Program in Liver Disease (private support by Gilead Sciences Ltd). **100.000 dollars**
Foreseen end of the project: December 2017.
- Project Title: Studio preliminare sulla disfunzione miocardica indotta da lipopolisaccaride nella ipertensione portale: ruolo nella genesi di insufficienza renale, potenziali effetti protettivi della simvastatina. (translation: Preliminary study on LPS-induced myocardial dysfunction in portal hypertension: role in the genesis of kidney failure, potential effects of simvastatin).
Funding source Amount (Euros): Linea 2 della ricerca, Università degli studi di Milano (Italian Minister of University and Research). **20.000 euro**
Foreseen end of the project: September 2017.

MAJOR COLLABORATIONS (still active in the last five years)

Name of collaborators-Topic-Affiliation (key-collaborations for the Albus proposal are underlined):

- 2012-at today-Armando Tripodi, Flora Peyvandi – hemostasis in liver diseases – Università degli studi di Milano, **ITALY**
- 2012-at today-Massimo Primignani, Massimo Colombo, Pietro Lampertico – clinical management of patients with cirrhosis and vascular liver diseases – Università degli studi di Milano, **ITALY**
- 2015-at today-Nicoletta Gagliano, Patrizia Procacci – morphological studies of the liver by light and electron microscopy – Università degli studi di Milano, **ITALY**
- 2015-at today-Joan Genesca – spontaneous porto-systemic shunt and clinical outcome in cirrhosis – Universitat Autònoma de Barcelona, **SPAIN**
- 2015-at today-Puneeta Tandon – muscle mass and risk of hepatic encephalopathy in cirrhosis – University of Alberta, Edmonton– **CANADA**
- 2015-at today-Augustin Albillos – liver disease in patients with Fontan cardiac-surgery – Universidad de Alcalá, Madrid, **SPAIN**

- 2016-2019-Guadalupe Garcia-Tsao, *role of ascites on hemodynamic response to non-selective beta-blockers* – University of Yale, **USA**
- 2005-at today-Jaime Bosch, *improvement of prognostic assessment in cirrhosis by hemodynamic study of the liver*, Universitat de Barcelona, **SPAIN**

PARTICIPATION TO INTERNATIONAL SCIENTIFIC GROUPS

- **2014-at today:** Research Network “**Baveno Cooperation group**”, international research network on portal hypertension-ROLE: steering committee
- **2014- at today:** Research Network “**VALDIG**”, international research network on vascular liver disease- ROLE: collaborator
- **2015- 2017:** Research Network “**CLIF Consortium**”, international research network on chronic liver failure-RUOLO: collaborator
- **2017- at today:** centro di ricerca coordinata “**A.M. e A. Migliavacca per lo Studio e la Cura delle Malattie del Fegato**”, Università degli studi di Milano-Fondazione IRCCS Ca’ Granda Policlinico ROLE: collaborator
- **2018- at today:** **Fondazione Luigi Villa** for the prevention and management of hemorrhagic and thrombotic diseases -ROLE: collaborator

MEMBERSHIPS OF SCIENTIFIC SOCIETIES

- **European Association for the Study of the Liver (EASL)**,
- **Associazione Italiana Studio Fegato (AISF)** (Italian Association for the study of the Liver),
- **Società Italiana di Medicina Interna (SIMI)** (Italian Society of Internal Medicine)

Awards and Honors:

- **Grants for research and awards:**
 1. April 2014-IRCCS Ca’ Granda research support for young investigators (20.000 euro) (Internal competition at the Hospital Ca’ Granda, University of Milan, where the PI worked from 2012 to 2014) (source: Italian Minister of Health, fondo 5XMille per la ricerca).
 2. April 2013-Gilead Sciences Research Scholars Program in Liver Disease (100.000 dollars) (private funding from Gilead Sciences)
 3. Highly scored PhD thesis in Medicine at the University of Barcelona, Spain, academic years 2009-2010
- **Travel grants for international meetings:**
 1. EASL YOUNG INVESTIGATORS’ BURSARIES - “full bursary” 42^o Annual Meeting of the European Association for the Study of the Liver (EASL)”. Barcelona, Spain 2007
 2. “EASL BASIC SCHOOL OF HEPATOLOGY, COURSE 3: VASCULAR BIOLOGY OF THE LIVER IN HEALTH AND DISEASE”, February 1-3, 2008; Lisbon, Portugal
 3. EASL YOUNG INVESTIGATORS’ BURSARIES - “full bursary” EASL monothematic: “NAFLD/NASH and Related Metabolic Disease”. Bologna, Italy 2009.
 4. EASL YOUNG INVESTIGATORS’ BURSARIES - “full bursary” 45th Annual Meeting of the European Association for the Study of the Liver (EASL)”. Vienna, Austria 2010.
 5. EASL YOUNG INVESTIGATORS’ BURSARIES - “full bursary” 46th Annual Meeting of the European Association for the Study of the Liver (EASL)”. Berlin, Germany 2011.
- **Young investigator Lecture**-Annual Meeting of the Italian Association for the Study of the Liver (AISF) 2019-title of the lecture: Cirrhosis and portal Hypertension